Search

Your search keyword '"Meissner, Y"' showing total 108 results
Start Over Author "Meissner, Y"
108 results on '"Meissner, Y"'

19. 2022 EULAR Points to consider for remote care in rheumatic and musculoskeletal diseases

Author

Clinical Psychology (onderzoeksprogramma), Leerstoel Geenen, de Thurah, A., Bosch, P., Marques, A., Meissner, Y., Mukhtyar, C.B., Zabotti, A., Knitza, J., Najm, A., Østerås, N., Pelle, T., Knudsen, L.R., Šmucrová, H., Berenbaum, F., Jani, M., Geenen, R., Krusche, M., Pchelnikova, P., de Souza, S., Badreh, S., Wiek, D., Piantoni, S., Gwinnutt, J.M., Duftner, C., Canhão, H., Quartuccio, L., Stoilov, N., Prior, Y., Bijlsma, J.W.J., Stamm, T.A., Dejaco, C., Clinical Psychology (onderzoeksprogramma), Leerstoel Geenen, de Thurah, A., Bosch, P., Marques, A., Meissner, Y., Mukhtyar, C.B., Zabotti, A., Knitza, J., Najm, A., Østerås, N., Pelle, T., Knudsen, L.R., Šmucrová, H., Berenbaum, F., Jani, M., Geenen, R., Krusche, M., Pchelnikova, P., de Souza, S., Badreh, S., Wiek, D., Piantoni, S., Gwinnutt, J.M., Duftner, C., Canhão, H., Quartuccio, L., Stoilov, N., Prior, Y., Bijlsma, J.W.J., Stamm, T.A., and Dejaco, C.

Published
2022

22. 2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases

Author

Thurah, A. de, Bosch, P., Marques, A., Meissner, Y., Mukhtyar, C.B., Knitza, J., Najm, A., Østerås, N., Pelle, T., Knudsen, L.R., Šmucrová, H., Berenbaum, F., Jani, M., Geenen, R., Krusche, M., Pchelnikova, P., Souza, S. de, Badreh, S., Wiek, D., Piantoni, S., Gwinnutt, J.M., Duftner, C., Canhão, H.M., Quartuccio, L., Stoilov, N., Prior, Y., Bijlsma, J.W., Zabotti, A., Stamm, Tanja A., Dejaco, C., Thurah, A. de, Bosch, P., Marques, A., Meissner, Y., Mukhtyar, C.B., Knitza, J., Najm, A., Østerås, N., Pelle, T., Knudsen, L.R., Šmucrová, H., Berenbaum, F., Jani, M., Geenen, R., Krusche, M., Pchelnikova, P., Souza, S. de, Badreh, S., Wiek, D., Piantoni, S., Gwinnutt, J.M., Duftner, C., Canhão, H.M., Quartuccio, L., Stoilov, N., Prior, Y., Bijlsma, J.W., Zabotti, A., Stamm, Tanja A., and Dejaco, C.

Abstract

Item does not contain fulltext, BACKGROUND: Remote care and telehealth have the potential to expand healthcare access, and the COVID-19 pandemic has called for alternative solutions to conventional face-to-face follow-up and monitoring. However, guidance is needed on the integration of telehealth into clinical care of people with rheumatic and musculoskeletal diseases (RMD). OBJECTIVE: To develop EULAR points to consider (PtC) for the development, prioritisation and implementation of telehealth for people with RMD. METHODS: A multidisciplinary EULAR task force (TF) of 30 members from 14 European countries was established, and the EULAR standardised operating procedures for development of PtC were followed. A systematic literature review was conducted to support the TF in formulating the PtC. The level of agreement among the TF was established by anonymous online voting. RESULTS: Four overarching principles and nine PtC were formulated. The use of telehealth should be tailored to patient's needs and preferences. The healthcare team should have adequate equipment and training and have telecommunication skills. Telehealth can be used in screening for RMD as preassessment in the referral process, for disease monitoring and regulation of medication dosages and in some non-pharmacological interventions. People with RMD should be offered training in using telehealth, and barriers should be resolved whenever possible.The level of agreement to each statement ranged from 8.5 to 9.8/10. CONCLUSION: The PtC have identified areas where telehealth could improve quality of care and increase healthcare access. Knowing about drivers and barriers of telehealth is a prerequisite to successfully establish remote care approaches in rheumatologic clinical practice.

Published
2022

25. 2022 EULAR Points to consider for remote care in rheumatic and musculoskeletal diseases

Author

de Thurah, A., Bosch, P., Marques, A., Meissner, Y., Mukhtyar, C.B., Zabotti, A., Knitza, J., Najm, A., Østerås, N., Pelle, T., Knudsen, L.R., Šmucrová, H., Berenbaum, F., Jani, M., Geenen, R., Krusche, M., Pchelnikova, P., de Souza, S., Badreh, S., Wiek, D., Piantoni, S., Gwinnutt, J.M., Duftner, C., Canhão, H., Quartuccio, L., Stoilov, N., Prior, Y., Bijlsma, J.W.J., Stamm, T.A., Dejaco, C., Clinical Psychology (onderzoeksprogramma), Leerstoel Geenen, Clinical Psychology (onderzoeksprogramma), and Leerstoel Geenen

Subjects
Patient Care Team, Epidemiology, Biochemistry, Genetics and Molecular Biology(all), education, Immunology, COVID-19, Biochemistry, Health Services Accessibility, Telemedicine, General Biochemistry, Genetics and Molecular Biology, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], Rheumatology, Humans, Health services research, Immunology and Allergy, Musculoskeletal Diseases, Pandemics, health care economics and organizations, Genetics and Molecular Biology(all)
Abstract

BackgroundRemote care and telehealth have the potential to expand healthcare access, and the COVID-19 pandemic has called for alternative solutions to conventional face-to-face follow-up and monitoring. However, guidance is needed on the integration of telehealth into clinical care of people with rheumatic and musculoskeletal diseases (RMD).ObjectiveTo develop EULAR points to consider (PtC) for the development, prioritisation and implementation of telehealth for people with RMD.MethodsA multidisciplinary EULAR task force (TF) of 30 members from 14 European countries was established, and the EULAR standardised operating procedures for development of PtC were followed. A systematic literature review was conducted to support the TF in formulating the PtC. The level of agreement among the TF was established by anonymous online voting.ResultsFour overarching principles and nine PtC were formulated. The use of telehealth should be tailored to patient’s needs and preferences. The healthcare team should have adequate equipment and training and have telecommunication skills. Telehealth can be used in screening for RMD as preassessment in the referral process, for disease monitoring and regulation of medication dosages and in some non-pharmacological interventions. People with RMD should be offered training in using telehealth, and barriers should be resolved whenever possible.The level of agreement to each statement ranged from 8.5 to 9.8/10.ConclusionThe PtC have identified areas where telehealth could improve quality of care and increase healthcare access. Knowing about drivers and barriers of telehealth is a prerequisite to successfully establish remote care approaches in rheumatologic clinical practice.

Published
2022

27. Register- und Kohortenstudien

Author

Meißner, Y., primary, Milatz, F., additional, Callhoff, J., additional, Minden, K., additional, Regierer, A., additional, and Strangfeld, A., additional

Published
2020
Full Text
View/download PDF

30. Malignancy and hospitalised infections in patients with RA treated with abatacept and other DMARDs: results from a 10-year international post-approval study

Author

Simon, TA, Suissa, S, Skovron, ML, Frisell, T, Askling, J, Michaud, K, Pedro, S, Strangfeld, A, Meissner, Y, Boers, M, Lacaille, D, Hochberg, M, Hoffman, V, and Gomez, A

Subjects
musculoskeletal diseases, ddc: 610, 610 Medical sciences, Medicine
Abstract

Background: The global post-marketing epidemiology programme for abatacept consists of observational studies based on registries and healthcare claims databases to assess malignancy and infection risks associated with abatacept treatment vs conventional synthetic (cs)DMARDs and other biologic (b) or[for full text, please go to the a.m. URL], 47. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 33. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 29. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2019
Full Text
View/download PDF

31. Psoriasis Arthritis und Schwangerschaft – eine systematische Literaturrecherche

Author

Meißner, Y, Fischer-Betz, R, and Strangfeld, A

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Derzeit gibt es keine einheitlichen Empfehlungen für die Betreuung von Patientinnen mit Psoriasis Arthritis (PsA) während der Schwangerschaft. Ziel dieser Arbeit war es, eine Übersicht zu Krankheitsaktivität und den Ausgang von Schwangerschaften bei Patientinnen mit PsA[zum vollständigen Text gelangen Sie über die oben angegebene URL], 47. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 33. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 29. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2019
Full Text
View/download PDF

32. Erste Erfahrungen mit Baricitinib aus dem rheumatologischen Alltag

Author

Meissner, Y, Kekow, J, Klopsch, T, Kühne, C, Zink, A, and Strangfeld, A

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Der Januskinase-Inhibitor Baricitinib wurde im Februar 2017 europaweit zur Behandlung der rheumatoiden Arthritis (RA) nach einem oder mehreren DMARD-Versagen zugelassen. Im Gegensatz zu Tofacitinib, das in den USA /der Schweiz schon seit 2012/2013 verfügbar ist, gibt es zu[zum vollständigen Text gelangen Sie über die oben angegebene URL], 46. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 32. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2019
Full Text
View/download PDF

36. Bei rheumatoider Arthritis ist frühes Therapieansprechen auf konventionelle synthetische DMARDs ein besserer Prädiktor für das Erreichen niedriger Krankheitsaktivität nach 12 und 24 Monaten als Autoantikörper und Erosionen

Author

Strangfeld, A, Richter, A, Baganz, L, Herzer, P, Kaufmann, J, Klopsch, T, Zinke, S, Meißner, Y, and Zink, A

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Nach europäischen und deutschen Empfehlungen sollen der Nachweis von ACPA oder Rheumafaktoren sowie frühe Erosionen für die Behandlungsentscheidung bei Patienten mit rheumatoider Arthritis herangezogen werden. Der prognostische Wert dieser Faktoren für das Erreichen von[zum vollständigen Text gelangen Sie über die oben angegebene URL], 45. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 31. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 27. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results